Innate Pharma S.A

(NASDAQ:IPHA)

Latest On Innate Pharma S.A (IPHA):

Date/Time Type Description Signal Details
2023-04-11 08:17 ESTNewsInnate Pharma: Exciting Company But Poor Stock In The U.S.N/A
2023-04-03 15:47 ESTNewsInnate stock surges ~15% after license deal with TakedaN/A
2023-03-23 13:19 ESTNewsInnate Pharma GAAP EPS of -€0.73, revenue of €57.67MN/A
2023-01-25 12:24 ESTNewsInnate, Sanofi licensing deal gets US antitrust clearanceN/A
2022-12-19 13:04 ESTNewsSanofi and Innate Pharma join hands for NK cell therapeutics in oncologyN/A
2022-10-04 11:33 ESTNewsInnate Pharma GAAP EPS of €0.08, revenue of €45.59MN/A
2022-10-04 11:33 ESTNewsInnate Pharma S.A. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-10-04 11:33 ESTNewsInnate Pharma S.A. (IPHA) First Half 2022 Financial Results and Business Update TranscriptN/A
2022-09-23 21:02 ESTNewsInnate says lacutamab shows response in blood/skin cancer patients in phase 2 trialN/A
2022-08-01 20:41 ESTNewsInnate stock slumps 16% as AstraZeneca pulls plug on monalizumab in head/neck cancer after trial failureN/A
2022-08-01 20:41 ESTNewsHot Stocks: BA jumps on Dreamliner news, HSBC gains on earnings, PSO also rises 10%, while IPHA sinksN/A
2022-07-21 07:01 ESTNewsInnate stock rises as Sanofi progress on 2nd cancer drug compound, pay €3MN/A
2022-06-03 13:55 ESTNewsInnate Pharma to get $5M from AstraZeneca as IPH5201 heads to phase 2 study in lung cancerN/A
2022-04-29 18:48 ESTNewsInnate Pharma stock rises on upcoming $50M from partner AstraZeneca, as dosing begins in lung cancer studyN/A
2022-03-25 10:19 ESTNewsInnate Pharma GAAP EPS of -€0.66, revenue of €24.7MN/A
2022-01-05 15:30 ESTNewsInnate Pharma obtains €28.7M non-dilutive financing in form of loansN/A
2021-12-09 14:12 ESTNewsInnate Pharma's monalizumab triplet combo shows anti-tumor activity in first-line head/neck cancerN/A
2021-10-07 01:54 ESTNewsInnate Pharma: Leading The NK Cell Immunotherapy SpaceN/A
2021-09-08 22:07 ESTNewsPRQR, LULU, BASE and RPHM among after hours moversN/A
2021-09-04 04:40 ESTNewsInnate Pharma rises 75% on announcement of presentations at medical meetingN/A
2021-09-04 04:40 ESTNewsInnate Pharma, Adagio top weekly healthcare gainers, Acasti Pharma, Forte Biosciences trailN/A
2021-09-03 08:42 ESTNewsInnate Pharma raised to outperform at SVB Leerink on upcoming catalystN/A
2021-09-02 12:48 ESTNewsInnate Pharma surges on upcoming presentation for AstraZeneca-partnered assetN/A
2021-07-22 16:14 ESTNewsInnate Pharma reports preliminary lacutamab data in mid-stage mycosis fungoides studyN/A
2021-07-22 16:13 ESTNewsInnate Pharma shelves avdoralimab trial after Phase 2 COVID-19 study failed; shares down 7%N/A
2021-03-17 23:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.59 to $6.58.Neutral
2021-03-17 15:26 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.61 to $6.59.Neutral
2021-03-13 22:08 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.63 to $6.61.Neutral
2021-03-13 05:56 ESTAnalyst RatingThe Analyst Target Price has increased from $6.59 to $6.63.Buy
2021-03-12 13:51 ESTAnalyst RatingThe Analyst Target Price has increased from $6.52 to $6.59.Buy
2021-03-12 06:18 ESTAnalyst RatingThe Analyst Target Price has increased from $6.51 to $6.52.Buy
2021-03-11 02:19 ESTAnalyst RatingThe Analyst Target Price has increased from $6.48 to $6.51.Buy
2021-03-10 06:37 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.52 to $6.48.Neutral
2021-03-09 02:21 ESTAnalyst RatingThe Analyst Target Price has increased from $6.51 to $6.52.Buy
2021-03-08 01:56 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.55 to $6.51.Neutral
2021-03-05 22:28 ESTAnalyst RatingThe Analyst Target Price has increased from $6.54 to $6.55.Buy
2021-03-05 13:43 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.56 to $6.54.Neutral
2021-03-04 02:24 ESTAnalyst RatingThe Analyst Target Price has increased from $6.54 to $6.56.Buy
2021-03-03 02:57 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.56 to $6.54.Neutral
2021-03-02 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $6.55 to $6.56.Buy
2021-02-28 13:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $8.35 to $6.55.Neutral
2021-02-28 02:10 ESTAnalyst RatingThe Analyst Target Price has increased from $6.6 to $8.35.Buy
2021-02-27 05:56 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.61 to $6.6.Neutral
2021-02-26 17:41 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.67 to $6.61.Neutral
2021-02-26 06:13 ESTAnalyst RatingThe Analyst Target Price has increased from $6.66 to $6.67.Buy
2021-02-25 00:01 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.67 to $6.66.Neutral
2021-02-23 22:36 ESTAnalyst RatingThe Analyst Target Price has increased from $6.64 to $6.67.Buy
2021-02-20 22:09 ESTAnalyst RatingThe Analyst Target Price has increased from $6.63 to $6.64.Buy
2021-02-20 02:10 ESTAnalyst RatingThe Analyst Target Price has increased from $6.6 to $6.63.Buy
2021-02-19 13:44 ESTAnalyst RatingThe Analyst Target Price has increased from $6.56 to $6.6.Buy

About Innate Pharma S.A (IPHA):

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.

IPHA Quotes by TradingView

See Advanced Chart

General

  • Name Innate Pharma S.A
  • Symbol IPHA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 247
  • Fiscal Year EndDecember
  • IPO Date2019-10-17
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.innate-pharma.com
View More

Valuation

  • Trailing PE 13.66
  • Price/Sales (Trailing 12 Mt.) 5.74
  • Price/Book (Most Recent Quarter) 1.39
  • Enterprise Value Revenue 4.28
  • Enterprise Value EBITDA 8.5
View More

Financials

  • Most Recent Quarter 2020-06-30
  • Profit Margin -70%
  • Return on Assets -8%
  • Return on Equity -23%
  • Revenue Per Share $0
  • Gross Profit 6.97 million
  • Quarterly Earnings Growth -37.9%
View More

Highlights

  • Market Capitalization 359.95 million
  • Analyst Target Price $6.58
View More

Share Statistics

  • Shares Outstanding 78.97 million
  • Shares Float 51.08 million
  • % Held by Insiders 155%
  • % Held by Institutions 2.27%
  • Shares Short 4853
  • Shares Short Prior Month 6773
  • Short Ratio 0.07
View More

Technicals

  • Beta 0.22
  • 52 Week High $8.23
  • 52 Week Low $3.55
  • 50 Day Moving Average 4.44
  • 200 Day Moving Average 4.47
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Innate Pharma S.A (IPHA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Innate Pharma S.A (IPHA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-03-312020-06-30$N/A-$0.07$0.00
2019-12-312020-03-31$41.85 million-$0.07-$0.1654.88%

Innate Pharma S.A (IPHA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Innate Pharma S.A (IPHA) Chart:

Innate Pharma S.A (IPHA) News:

Below you will find a list of latest news for Innate Pharma S.A (IPHA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Innate Pharma S.A (IPHA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest IPHA Trades:

Date Shares Price
Jun 13, 2022 7:02 PM EST1$2.6

Innate Pharma S.A (IPHA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320004510/0001171843-20-004510-index.htm
2019-07-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1598599/000000000019010756/0000000000-19-010756-index.htm
2019-07-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1598599/000000000019011750/0000000000-19-011750-index.htm
2019-10-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1598599/000093583619000556/0000935836-19-000556-index.htm
2020-02-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1598599/000095010320001698/0000950103-20-001698-index.htm
2019-06-10DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1598599/000095012319005898/0000950123-19-005898-index.htm
2019-07-19DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1598599/000095012319006509/0000950123-19-006509-index.htm
2019-07-19DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1598599/000095012319006513/0000950123-19-006513-index.htm
2019-08-30DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1598599/000095012319008748/0000950123-19-008748-index.htm
2019-08-30DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1598599/000095012319008751/0000950123-19-008751-index.htm
2019-10-25SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1598599/000110465919056493/0001104659-19-056493-index.htm
2019-12-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184319007999/0001171843-19-007999-index.htm
2019-12-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184319008007/0001171843-19-008007-index.htm
2019-12-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184319008091/0001171843-19-008091-index.htm
2020-01-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320000005/0001171843-20-000005-index.htm
2020-01-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320000124/0001171843-20-000124-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320000216/0001171843-20-000216-index.htm
2020-03-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320001581/0001171843-20-001581-index.htm
2020-03-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320001582/0001171843-20-001582-index.htm
2020-04-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320002592/0001171843-20-002592-index.htm
2020-04-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320002598/0001171843-20-002598-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320002678/0001171843-20-002678-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320002845/0001171843-20-002845-index.htm
2020-04-2420-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1598599/000117184320002847/0001171843-20-002847-index.htm
2020-04-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320002932/0001171843-20-002932-index.htm
2020-05-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320003351/0001171843-20-003351-index.htm
2020-05-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320003611/0001171843-20-003611-index.htm
2020-05-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320003689/0001171843-20-003689-index.htm
2020-05-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320003852/0001171843-20-003852-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320004510/0001171843-20-004510-index.htm
2020-07-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320004976/0001171843-20-004976-index.htm
2020-07-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320005318/0001171843-20-005318-index.htm
2020-08-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320005816/0001171843-20-005816-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320005838/0001171843-20-005838-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320006299/0001171843-20-006299-index.htm
2020-10-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320007004/0001171843-20-007004-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320007194/0001171843-20-007194-index.htm
2020-11-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1598599/000117184320007634/0001171843-20-007634-index.htm
2019-09-20F-1Registration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1598599/000119312519250682/0001193125-19-250682-index.htm
2019-10-04F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1598599/000119312519262824/0001193125-19-262824-index.htm
2019-10-108-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1598599/000119312519265818/0001193125-19-265818-index.htm
2019-10-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1598599/000119312519266732/0001193125-19-266732-index.htm
2019-10-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1598599/000119312519266743/0001193125-19-266743-index.htm
2019-10-17POS EXPost-effective amendment adding exhibits to registration statement [Rule 462(d)]https://www.sec.gov/Archives/edgar/data/1598599/000119312519268738/0001193125-19-268738-index.htm
2019-10-17FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1598599/000119312519268841/0001193125-19-268841-index.htm
2019-10-17FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1598599/000119312519268845/0001193125-19-268845-index.htm
2019-10-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1598599/000119312519270053/0001193125-19-270053-index.htm
2019-10-03F-6Registration of American Depository Receipt shares, not immediately effectivehttps://www.sec.gov/Archives/edgar/data/1598599/000119380519000894/0001193805-19-000894-index.htm
2019-10-09F-6/ARegistration of American Depository Receipt shares, not immediately effectivehttps://www.sec.gov/Archives/edgar/data/1598599/000119380519001209/0001193805-19-001209-index.htm
2019-10-16CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1598599/000135445719000527/0001354457-19-000527-index.htm
2014-01-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1598599/000159859914000001/0001598599-14-000001-index.htm
2019-10-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1598599/999999999519002325/9999999995-19-002325-index.htm
2019-10-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1598599/999999999519002357/9999999995-19-002357-index.htm
2019-09-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1598599/999999999719006702/9999999997-19-006702-index.htm
2019-10-01SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1598599/999999999719007193/9999999997-19-007193-index.htm